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Abstract 
Primary percutaneous coronary intervention (PCI) is nowadays the preferred reperfusion 
strategy for patients with acute ST-segment elevation myocardial infarction (STEMI), aiming at 
restoring epicardial infarct-related artery patency, and achieving microvascular reperfusion as early 
as possible, thus limiting the extent of irreversibly injured myocardium. Yet, in a sizeable proportion 
of patients, primary PCI does not achieve an effective myocardial reperfusion due to the occurrence 
of coronary microvascular obstruction (MVO). 
The amount of infarcted myocardium, the so-called infarct size, has long been known to be 
an independent predictor for major adverse cardiovascular events (MACE) and adverse left 
ventricular (LV) remodelling after myocardial infarction. Previous cardioprotection studies were 
mainly aimed at protecting cardiomyocytes and reducing infarct size. However, several clinical and 
preclinical studies have reported that the presence and extent of MVO represents another important 
independent predictor of adverse LV remodelling, and recent evidences support the notion that MVO 
may be more predictive of MACE than infarct size itself. Although timely and complete reperfusion 
is the most effective way of limiting myocardial injury and subsequent ventricular remodelling, there 
are currently no other effective therapeutic strategies that have been translated into improved clinical 
outcomes. Of importance, despite the presence of a large number of studies focused on infarct size, 
only few cardioprotection studies addressed MVO as a therapeutic target.  
In this review, we provide a detailed summary of MVO including underlying causes, 
diagnostic techniques, and current therapeutic approaches. Furthermore, we discuss the hypothesis 
that simultaneously addressing infarct size and MVO may help to translate cardioprotective strategies 
into improved clinical outcome following STEMI.  
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Introduction 
Advances in the treatment of patients with acute ST-segment elevation myocardial infarction 
(STEMI) have resulted in a decline in mortality over the past 4 decades (1), with 1-year cardiac 
mortality in patients with STEMI reaching a plateau of ≈7-8% (2,3). However, although national 
system delays for patients undergoing primary percutaneous coronary interventions (PCI) have been 
significantly improved over recent years, in-hospital mortality has remained substantially unchanged 
(4,5). Moreover, morbidity caused by development of post–myocardial infarction (MI) left 
ventricular (LV) remodelling and heart failure remains significant and is on the rise (3). In particular, 
1 in 5 patients may be hospitalised with heart failure within 12 months of presenting with an anterior 
STEMI (3). 
Infarct size has long been known to be an independent predictor of adverse LV remodelling 
after MI (6). In addition to infarct size, several clinical and preclinical studies have reported that the 
presence and extent of microvascular obstruction (MVO) represents an important independent 
predictor of adverse LV remodelling (7), and recent evidences support the notion that MVO may be 
more predictive of major adverse cardiovascular events (MACE) than infarct size itself (8). 
Although timely and complete reperfusion is the most effective way of limiting myocardial 
injury and subsequent ventricular remodelling (9), there are currently no other effective therapeutic 
strategies for reducing infarct size or MVO that have been translated into improved clinical outcomes, 
despite tremendous research efforts in this field (5,10). There may be several explanations including 
imperfect study design and true lack of efficacy. For example, in the field of cardioprotection, 
preclinical data may be inadequate, and study design problems relate to patient selection and/or 
inappropriate timing and mode of delivery of the cardioprotective agent (11). Moreover previous 
cardioprotection studies were mainly aimed at protecting cardiomyocytes and reducing infarct size, 
neglecting other targets notably the coronary microcirculation (10,11). On the contrary, infarct size 
and MVO represent two complementary therapeutic targets for cardioprotection trials.  
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In this review, we discuss the hypothesis that an integrated therapeutic approach 
simultaneously addressing both irreversible myocardial injury and MVO may help to effectively 
translate cardioprotective strategies into improved clinical outcome for STEMI patients. 
 
Mechanisms underlying MVO during STEMI 
Microvascular obstruction refers to the inability to reperfuse the coronary microcirculation 
(microvessels, <200 µm diameter) in a previously ischemic region, despite opening of the epicardial 
vessel (12,13). Mechanisms underlying myocardial injury and MVO are multiple and interacting (13) 
(Figure 1). Ischemic injury represents a well-known mechanism responsible for cardiomyocyte death, 
and when ischemia lasts >3 h, the adverse effects of ischemia-associated injury become all the more 
pronounced (14-17). However, besides effects on cardiomyocytes, ischemia/reperfusion injury may 
also damage other cell types, in particular endothelial cells. Notably, apoptosis of endothelial cells 
seems to precede cardiomyocyte cell apoptosis during ischemia/reperfusion injury (18). Initial studies 
in the dog using electron microscopic analysis after 90 min of coronary artery occlusion followed by 
reperfusion revealed severe capillary damage, endothelial protrusions and blebs that appeared to 
block the capillary lumen, and endothelial gaps with extravascular erythrocytes that in turn may 
favour the occurrence of intramyocardial haemorrhage (IMH) (19). MVO is caused by further 
obliteration of vessel lumen by neutrophil-platelet aggregates, which in turn produce large amount of 
vasoconstrictors and inflammatory mediators (13,19). Furthermore, intense interstitial myocardial 
edema occurring upon reperfusion compresses capillaries and small arterioles, further decreasing 
flow through these dysfunctional vessels (20). 
Distal embolization is another important mechanism contributing to both myocardial injury 
and MVO. Coronary micro-embolization in experimental models causes regional contractile 
dysfunction. Of note, myocardial perfusion starts falling when microspheres obstruct >50% of 
coronary capillaries (21). Thus, the small number of emboli during primary PCI in the setting of 
STEMI, although not affecting myocardial perfusion may create a local reacting milieu with release 
 6 
of inflammatory and vasoactive substances from coronary plaque such as endothelin-1, tissue factor 
and microparticles, which have the potential to increase the severity of the functional impairment of 
the coronary circulation (22). Moreover, in patients with STEMI, the coronary neutrophil 
extracellular traps (NETs) burden correlates negatively with ST-segment resolution (STR) and 
positively with infarct size, thus suggesting that NETs may propagate thrombosis and inflammation 
distally into the infarcted myocardium and contribute to myocyte death during atheroembolism (23). 
Finally, oxidative stress and ischemia per se reduce the bioavailability of nitric oxide, further 
contributing to the dysfunction of the myocardial microcirculation (13). 
Another pathogenic mechanism causing MVO is represented by individual susceptibility to 
microvascular dysfunction, related to the function, as well as to the structure and the density of the 
microcirculation (24). Genetic factors may modulate adenosine-induced vasodilation (i.e. 1976T.C 
polymorphism of the adenosine 2A receptors gene was suspected to be related with a higher 
prevalence of MVO) (13). Moreover, genetic variations within defined regions of VEGFA and 
CDKN2B-AS1 genes have been shown to be associated with coronary microvascular dysfunction, 
whereas sex-specific allelic variants within MYH15, VEGFA, and NT5E genes seem to be related 
with an increased risk of coronary microvascular dysfunction in men (25). Another factor modulating 
individual susceptibility to MVO is the presence of ischemic preconditioning (IPC), which not only 
protects the myocardium but might also protect the coronary microcirculation (13). Accordingly, pre-
infarction angina might help preventing cardiomyocyte death and MVO by inducing IPC. 
Importantly, beneficial effect of pre-infarction angina may be blunted in humans due to risk factors 
or drugs therapy affecting unfavourably IPC (26).  
Finally, pre-existing microvascular dysfunction, particularly in patients with multiple 
cardiovascular risk factors, may be associated with an increased risk of developing MVO (13). 
Indeed, pre-existent microvascular dysfunction might represent an important pathogenetic 
component of MVO, as previous studies demonstrated that coronary blood flow is reduced by 50% 
in the non-culprit coronary arteries during acute MI, before and after primary PCI, thus confirming a 
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global rather than a regional myocardial microcirculatory impairment (27). Moreover, also known 
cardiovascular risk factors have been shown to predispose to MVO. In particular, acute 
hyperglycemia, which was independent on previous glycemic control evaluated by glycosylated 
hemoglobin A1c levels, is associated with a higher risk of developing MVO, therefore suggesting a 
direct detrimental effect on reperfusion injury (28). Moreover, in diabetic patients, disturbances in 
glucose metabolism per se may also have a negative impact on myocardial reperfusion, as elevated 
levels of free fatty acids during hyperglycemia reduce endothelium-derived vasodilation of the 
myocardial vasculature (29) and hyperglycemia causes the plugging of leukocytes in the 
microvasculature of the myocardium and increases pro-coagulable properties of platelets (30). Also 
dyslipidemia may predispose to MVO. Indeed, hypercholesterolemia may impair vascular wall 
function and structure, interfering with endothelial function (31), along with a possible role in the 
delayed healing after ischemia/reperfusion injury (32). Moreover, hypercholesterolemia may cause a 
near-complete abrogation in vascular nitric oxide (NO) bioavailability, elevated oxidative stress, and 
a pro-inflammatory milieu, conditions associated with an impaired vascular reactivity (31). 
Hypertension is also involved in the predisposition to MVO. Indeed, hypertension is linked to 
endothelial dysfunction, along with ultra-structural remodeling of cardiac microvessels, that can 
cause a progressive impairment of flow-mediated vasodilation. Also advanced age has been shown 
to be an independent predictor of MVO (33). 
 
Diagnostic techniques for MVO assessment 
Patients presenting with STEMI may develop MVO, with a variable prevalence ranging from 
5% up to 60%, according to the methods used to assess the phenomenon and to the population under 
study (13). Indeed, MVO can be assessed using different techniques and at different time points after 
STEMI. 
CMR represents the reference standard technique for in-vivo MVO detection and 
quantification (13,34). On contrast-enhanced CMR, MVO is identified as a dark hypointense core 
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within the areas of hyperenhancement on either early gadolinium enhancement (referred to as early 
MVO) or conventional late gadolinium enhancement (referred to as late MVO) (34). Early and late 
MVO are assessed approximately 1 and 15 minutes after gadolinium injection, respectively. Since 
the presence and extent of MVO diminish over time, early MVO is more sensitive to less pronounced, 
subtle microvascular injury. Its prognostic value for the prediction of post-infarction adverse events, 
however, is low. In contrast, late MVO reflects severely disturbed microcirculation and is strongly 
associated with clinical outcome (34). Apart from the impact of different imaging techniques, CMR 
measurements of MVO are also affected by the timing of image acquisition after infarction due to the 
dynamic course of microvascular injury. Therefore, STEMI trials require predefined CMR protocols 
for the entire study population to ensure the validity of the acquired data. The imaging protocols in 
previous studies, however, were quite heterogeneous, which hampers inter-study comparisons and 
collaborative research with data merging. The international standardization of post-infarction CMR 
imaging protocols is currently elaborated and urgently needed to overcome the mentioned drawbacks 
and further strengthen CMR as the reference method to evaluate myocardial damage (34,35). MVO 
can be also detected at coronary angiography (defined as Thrombolysis In Myocardial Infarction 
[TIMI] flow grade <3 or 3 with a myocardial blush grade [MBG] 0 to 1), by myocardial contrast 
echocardiography, as an incomplete STR on ECG (13), or directly by invasive measurement of the 
index of microvascular resistance (IMR) using a diagnostic guidewire (13). This technique is 
appealing since IMR can be measured immediately during primary PCI identifying in the 
catheterization laboratory high-risk patients with an increased IMR requiring a more intensive therapy 
targeting MVO. Indeed, patients with a high value of IMR (>40 U) at the time of primary PCI might 
likely benefit from a more aggressive therapeutic approach (i.e. infusion of glycoprotein IIb/IIIa 
inhibitors, intracoronary thrombolysis or vasodilators). On the other hand, patients with low values 
of IMR (<40 U) will not be subjected to aggressive therapies with the unnecessary risk of adverse 
events such as bleeding. At the same time, it should be noted that, among the available methods, IMR 
has the highest predictive accuracy for identifying patients at risk of myocardial haemorrhage (36). 
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Correlation between infarct size and MVO 
 Evidence derived from trials and meta-analyses has demonstrated that morbidity and mortality 
after STEMI are closely related to infarct size. In particular, a recent meta-analysis of 2632 patients 
from 10 randomized controlled trials showed that infarct size measured by CMR or single-photon 
emission computed tomography, within a month after primary PCI, was strongly associated with 1-
year hospitalization for heart failure and all-cause mortality (37). Of note, for every 5% increase in 
MI size, there was a 20% increase in the relative hazard ratio for 1-year hospitalization for heart 
failure and all-cause mortality (37). However, recent evidence suggests that MVO may be more 
predictive of clinical outcome after primary PCI than infarct size itself (38) (Figure 2). Indeed, in a 
patient-level meta-analysis of 1025 patients from 8 studies, Van Kranenburg and colleagues (39) 
showed that the presence of MVO was an independent predictor of MACE at 2 years in patients with 
STEMI, whereas MI size was not independently associated with adverse events. Moreover, a more 
recent patient-level meta-analysis from 7 randomized controlled trials (n=1688) by de Waha et al. 
(40) confirmed the prognostic value of MVO over MI size for mortality and hospitalisation for heart 
failure at 1-year. Of note, in the fully adjusted model, every 1% absolute increase in MVO extent was 
independently associated with a 14% relative increase in 1-year all-cause mortality and an 8% 
increase in 1-year heart failure hospitalisation. Moreover, anterior infarct location, baseline TIMI 
flow, and symptom-to-device time were not significant predictors of outcomes in these adjusted 
models, suggesting that their prognostic impact may be mediated through larger areas of MVO (40). 
Similar findings were obtained by Symons et al. in a longitudinal study of 810 patients after a median 
follow-up of 5.5 years (41). 
 It is well known that patients with larger MI are more likely to develop MVO (11,35). 
However, pathophysiologic mechanisms through which MVO adversely impacts prognosis and 
demonstrated a superior prognostic value over MI size are likely multiple and not completely 
understood. Indeed, beyond cardiomyocyte injury, severe microvascular damage after STEMI has 
been shown to be associated with extravasation of red blood cells leading to IMH (35,42) (Figure 3). 
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Animal and human studies demonstrated that, in contrast to the non-reperfused myocardium, 
microvascular reperfusion injury is associated with IMH (43,44). Two possible mechanisms link 
MVO and IMH. The first mechanism suggests that hemorrhage leads to myocardial swelling and 
compression on the microvasculature, which in turn worsens MVO. In the second plausible 
mechanism, it is the microvascular injury and obstruction that lead to endothelial damage and 
subsequent leakage of blood cells to the interstitium. Of note, IMH was found to be associated with 
the duration of ischemia and necrosis, and represented a hallmark of reperfusion, while no IMH was 
observed in animals with permanent coronary occlusion (45). CMR studies demonstrated that IMH 
occurs in ~40% of STEMI patients (35), and while MVO is present in all patients with IMH, 
hemorrhage does not have to present with MVO (46). Of importance, recent data revealed that IMH 
occurring in the acute phase after primary PCI leads to residual myocardial iron deposition that has 
been shown to induce, in the sub-acute phase, a prolonged inflammation favouring the occurrence of 
adverse LV remodelling (42,47). Indeed, CMR studies showed that IMH was closely related to the 
development of adverse LV remodelling and worse clinical outcomes (48) and a study by Carrick et 
al. (42) showed that IMH was more closely associated with adverse clinical outcomes than MVO 
(49). On the other hand, the occurrence of MVO in the acute phase after STEMI may limit the delivery 
of endogenous promoters responsible for post-infarction remodelling, as well as macrophages 
required for phagocytosis of cellular debris needed for optimal infarct healing (50). In conclusion, 
beyond cardiomyocyte injury, MVO may contribute to a worse prognosis by blunting a “positive” 
inflammatory response in the acute phase and, through development of IMH and residual iron 
deposits, stimulating a prolonged intramyocardial inflammatory reaction that in turn could promote 
LV remodelling. 
 
Current therapeutic approaches addressing infarct size reduction and MVO 
 Several pharmacological and non-pharmacological therapies have been evaluated in the last 
decades in cardioprotection studies (see Table 1). 
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Drugs 
Beta-blockers 
Most of the clinical studies have evaluated the effect of ß-blockers on infarct size and 
cardiomyocyte protection, but only few pre-clinical studies have explored possible effects on MVO. 
Data from a large-animal MI model found that intravenous administration of the ß1-selective blocker, 
metoprolol, prior to reperfusion, reduced MI size (51), and reduced the occurrence of MVO by 
modulating the inflammatory response during the acute phase of MI and inhibiting the formation of 
neutrophil-platelet aggregates (52). Moreover, pre-clinical studies showed that the third generation 
ß-blockers like carvedilol and nebivolol are able to protect the coronary microcirculation and thereby 
reduce infarct size (53,54). 
In the METOCARD-CNIC trial, which enrolled 270 patients with anterior STEMI, 
intravenous metoprolol (3x5mg) administered in the ambulance prior to primary PCI reduced MI 
size, prevented LV adverse remodelling, preserved LV systolic function, and lowered hospital 
readmissions for heart failure (55,56). Of note, the cardioprotective effect of metoprolol was time-
dependent (57). Moreover, a subanalysis of the METOCARD-CNIC trial (52) demonstrated a 
significant interaction between metoprolol treatment and the correlation between leukocyte count and 
MVO. In particular, a significant positive correlation between neutrophil count and the extent of 
MVO was only present in control patients (that is, not receiving metoprolol), while in patients 
receiving i.v. metoprolol before reperfusion there was no sign of association between total leukocyte 
or neutrophil counts and the extent of MVO, suggesting that the administration of i.v. metoprolol 
during ongoing MI does not affect the circulating levels of leukocytes but modulates the impact of 
neutrophils on MVO.  
On the contrary, the EARLY BAMI trial failed to report a reduction in MI size at 1-month 
(assessed by CMR) with IV metoprolol (2x5mg) administered just before primary PCI in STEMI 
patients presenting within 12 h of symptom onset (58). The reasons for the neutral results of the 
EARLY BAMI trial vs. the METOCARD-CNIC trial may include: dosing (10 vs. 15 mg), timing 
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(most benefit observed with metoprolol given soon after STEMI onset) and patient population (all-
comers vs. anterior STEMI) (10). Of note, current ESC STEMI guidelines propose that IV beta-
blockers should be considered at the time of presentation in patients undergoing primary PCI without 
contraindications, with no signs of acute heart failure, and with a systolic blood pressure  >120 mmHg 
(Class of recommendation IIa, level of evidence A) (5). 
 
Adenosine 
Adenosine is an endogenous nucleoside characterized by a short half-life (<2 s) and 
by pleiotropic effects (59). Of importance, adenosine is a potent direct vasodilator of coronary 
microcirculation through stimulation of A2 receptors and, it also exhibits anti-inflammatory 
properties against neutrophils and inhibits platelet aggregation (59,60). Moreover, adenosine 
mimics IPC limiting reperfusion injury (59), and it exhibits antiapoptotic effects and may 
stimulate angiogenesis (59). Clinical studies of acute MI with adenosine administered at the time of 
reperfusion have displayed mixed results in terms of improvement of MVO and MI size, with post-
hoc analyses suggesting beneficial effects in STEMI patients presenting within 3 h of symptom onset 
(61,62). In the REOPEN-AMI trial, high dosages of intracoronary adenosine, given after thrombus 
aspiration through the aspiration catheter, demonstrated a significant improvement of MVO, assessed 
by STR, and enzymatic infarct size when compared with placebo or sodium nitroprusside, which 
translated into a reduction of MACE and a better LV remodelling at 1-year follow-up (63,64). 
However, the REFLO-STEMI trial enrolling 247 patients presenting within 6 h of symptom onset 
failed to confirm these results (65). In fact, compared with controls, intracoronary adenosine was 
associated similar amount of MVO, but with an increase in infarct size and MACE at 30 days and 6 
months, and LV ejection fraction was reduced. Interestingly, a meta-analysis of clinical studies 
undertaken in the primary PCI era has demonstrated a beneficial effect of intracoronary adenosine in 
terms of less heart failure following STEMI (66). 
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Exenatide 
Experimental studies in diabetic rats demonstrated that exenatide, a synthetic version of the 
glucagon-like-peptide-1 (GLP-1) analogue, exendin-4, might protect the coronary microcirculation 
against oxidative stress, apoptosis, and the resultant microvascular barrier dysfunction in diabetes 
(67), Moreover, the GLP-1 receptor is also present on cardiomyocytes and infusion of GLP-1 has 
been shown to activate anti-apoptotic pathways and increase myocardial metabolic efficiency in 
preclinical and clinical studies (68,69). Of importance. exenatide reduced MI size when administered 
prior to reperfusion (70) in studies with animal MI model, and two small proof-of-concept clinical 
studies in STEMI patients have reported beneficial effects with exenatide initiated prior to primary 
PCI (71,72), with the most benefit observed in those STEMI patients presenting within 132 min of 
symptom onset (73). However, these findings did not translate into improved long-term clinical 
outcomes, and a recent study by Roos et al. (74) failed to find any beneficial effect of exenatide on 
infarct size normalized for area-at-risk (AAR). The ongoing Exenatide for Myocardial Protection 
During Reperfusion Study is also testing the effect of IV exenatide on final MI size at 3 months over 
AAR at 72 h post-randomization (assessed by CMR). However, it should be noted that, currently, no 
studies have hitherto evaluated the effect of exenatide on MVO. 
 
Statins 
In the STATIN STEMI trial enrolling 171 patients with STEMI administration of high doses 
of statins prior to primary PCI has been found to improve angiographic MVO but not to reduce infarct 
size when compared with low doses (75). Moreover, a post hoc analysis from the SECURE-PCI 
(Statins Evaluation in Coronary Procedures and Revascularization) trial, showed that the subgroup 
of 865 patients undergoing primary PCI had a nearly 50% reduction in 30-day MACE with high-dose 
atorvastatin (administered prior and 24 h after primary PCI) compared with placebo (76). At the same 
time, an ongoing statin therapy at the time of STEMI was associated to a lower rate of MVO, a better 
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functional recovery of myocardial function after 6 months of follow-up (77) and a reduced infarct 
size (78) when compared with patients not on statin. 
 
Atrial natriuretic peptide 
Experimental studies demonstrated that atrial natriuretic peptide (ANP) may supress 
endothelin-1 production in endothelial cells (79) with possible favourable effects on MVO (80). On 
the contrary, another animal study demonstrated that ANP may enhance myocardial inflammatory 
infiltration in the early phase after MI, thus worsening MVO (81). Of importance, the J-WIND trial 
has demonstrated a reduction in enzymatic infarct size in STEMI patients treated with an infusion of 
carperitide (an ANP agonist) prior to primary PCI (82). However, the effect of ANP on MVO has 
never been investigated in clinical studies (13). 
 
Antiplatelet therapy 
Recent experimental data have suggested that the platelet P2Y12 inhibitors may reduce infarct 
size when administered at the onset of reperfusion, conferring a “postconditioning-like” protection 
(83). However, a sub-analysis of PLATO trial, did not find differences with regard to myocardial 
perfusion between clopidogrel and ticagrelor (84) and in the large ATLANTIC study, pre-hospital 
administration of ticagrelor, in patients with acute STEMI, did not improve pre-PCI coronary 
reperfusion as assessed by STR (85). The REDUCE-MVI trial did not find any differences in MVO 
or infarct size between ticagrelor and prasugrel (86). Currently, the PITRI trial is ongoing and is 
testing if intravenous cangrelor administered prior to reperfusion will reduce the incidence of MVO 
and limit infarct size in STEMI patients treated with primary PCI (87). Moreover, results from clinical 
studies evaluating pre-hospital administration of glycoprotein IIb/IIIa inhibitors have been mixed. 
Data initially suggesting improved outcome with the routine use of glycoprotein IIb/IIIa inhibitors 
were mostly derived from investigations in the pre-stent era and prior to the routine use of dual 
antiplatelet therapy. More contemporary studies did not exhibit benefits in patients receiving 
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glycoprotein IIb/IIIa inhibitors in addition to primary PCI and dual antiplatelet therapy. Indeed, the 
FINESSE trial demonstrated that upstream administration of abciximab with half-dose reteplase 
significantly reduces infarct size but does not have any overall clinical benefit in primary study 
endpoint at 90 days as well as in mortality at 1 year (88). A pooled meta-analysis of 16 randomized 
trials involving 10,085 patients found similar rates of 30-day mortality and re-infarction whereas the 
risk of major bleeding complications was significantly increased in the glycoprotein IIb/IIIa group 
(89). On the other hand, the On-TIME-2 trial showed that a routine pre-hospital initiation of high-
bolus dose tirofiban might improve STR and clinical outcome after PCI (90). Finally, Amier et al. 
(91) in a retrospective post-hoc analysis recently showed that anterior STEMI and the use of 
glycoprotein IIb/IIIa inhibitors were associated with the development of IMH. 
The route of glycoprotein IIb/IIIa inhibitor administration was also subject of clinical 
investigations since higher local concentrations and increased levels of platelet receptor occupancy 
can be achieved with intracoronary compared to standard intravenous application (92). The INFUSE-
AMI (Intracoronary abciximab and aspiration thrombectomy in patients with large anterior 
myocardial infarction) study reported a significant reduction of infarct size assessed with CMR 
imaging after intracoronary administration of abciximab compared to no abciximab in 452 STEMI 
patients with large anterior infarctions (93). The Abciximab Intracoronary versus intravenous Drug 
Application in STEMI (AIDA STEMI) trial was the only investigation, which was powered for 
clinical outcomes and directly compared both routes of administration in 2,065 STEMI patients (94). 
Intracoronary, as compared to intravenous abciximab, resulted in a similar rate of MACE (all-cause 
death, re-infarction, or new congestive heart failure) after 90 days and 1 year (94,95). Consistently, 
the CMR substudy, which enrolled 795 patients, demonstrated no differences between groups with 
respect to myocardial damage and reperfusion injury, including a similar extent of MVO (96). Of 
note, glycoprotein IIb/IIIa inhibitors represent the only therapy to treat MVO proposed in the current 
ESC STEMI guidelines, suggesting that they should be considered for bailout if there is evidence of 
no-reflow or a thrombotic complication (class of recommendation IIa, level of evidence C) (5). 
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Mitochondria-targeted approaches 
Cyclosporine-A has been advocated as a cardioprotective drug by inhibiting MPTP opening 
during ischemia-reperfusion injury. Of interest, an initial proof-of-concept clinical study suggested a 
benefit deriving from an IV bolus of Cyclosporine-A, administered prior to reperfusion, by reducing 
infarct size and occurrence of adverse LV remodelling (3,75). However, two subsequent large 
multicentre randomized clinical trials have failed to demonstrate a reduction in MI size or improved 
clinical outcomes with Cyclosporine-A administered prior to primary PCI in STEMI patients 
(3,97,98). Of interest, the recent NACIAM trial (99) demonstrated that IV administration of high-
dose of N-acetylcysteine (NAC, 29 g over 48h), an antioxidant drug, combined with low-dose 48 h 
infusion of nitroglycerin reduced infarct size. The cardioprotective effect of NAC was mainly 
attributed to the ability to scavenge reactive oxygen species (ROS), especially at the level of 
mitochondria. On the other hand, the LIPSIA-NACC trial demonstrated no benefit of a lower dose of 
NAC (2.4 g over 48 h) compared with placebo in terms of myocardial salvage index assessed by 
CMR (100). 
 
Ischemic conditioning 
Experimental studies over the last three decades demonstrated a cardioprotective role for 
ischemic conditioning (10,11). In particular, remote ischemic conditioning (RIC), using one or more 
cycles of brief limb ischemia and reperfusion, has been found in both small and large animal MI 
models to reduce infarct size (101). Moreover, several clinical studies have shown a reduced infarct 
size or increased myocardial salvage in STEMI patients undergoing RIC and treated with primary 
PCI, as assessed by both serum cardiac enzyme release and cardiac imaging (SPECT, CMR) (102-
105) and this benefit was associated with an improvement of T2-weighted edema volume assessed 
by CMR and STR (103). Moreover, cardioprotection by combined intrahospital RIC and 
postconditioning in addition to primary PCI significantly reduced the rate of MACE and new 
congestive heart failure after STEMI (106). However, a recent study by Verouhis et al. (107), 
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enrolling 93 anterior STEMI patients did not demonstrate a reduced infarct size as a percentage of 
the AAR (assessed by CMR at 4–7 days). The CONDI trial randomized 333 STEMI patients to 
receive RIC or not in the ambulance during transportation to primary PCI. In the per protocol analysis 
of 251 patients, mean myocardial salvage index was higher in patients treated with RIC. In a 
secondary analysis involving longer-term follow-up to 4-years, compared with control treatment, RIC 
was associated with reductions in all-cause mortality and MACCE (108) and a lowered economic 
deriving from reduced hospitalisations for heart failure (108). Some limitations of this trial include 
comparatively few primary outcome events (n=49). Of note, statin use was associated with an 
increased efficacy of RIC to reduce infarct size (110). However, these studies were underpowered for 
clinical outcome analyses, and the ongoing CONDI-2/ERICPPCI trial, which will investigate the 
effect of RIC on cardiac death and hospitalisation for heart failure at 1-year in reperfused STEMI 
patients, will shed further light on this topic. 
 
Intracoronary fibrinolysis 
In a proof-of-concept randomized controlled trial, Sezer et al. reported that intracoronary 
administration of a reduced dose (250 kU) of streptokinase via the guiding catheter at the end of 
primary PCI improves myocardial reperfusion (110), instigating other clinical trials, such as T-TIME 
(NCT02257294), OPTIMAL (NCT02894138), RESTORE-MI (ACTRN12618000778280), 
STRIVE (NCT03335839) and a trial of intracoronary tenecteplase vs. abciximab (2010-022725-16). 
Two of these trials have recently reported (112,113). The T-TIME investigators tested the hypothesis 
that a strategy involving low dose intra-coronary fibrinolytic therapy with alteplase (10 mg or 20 mg) 
infused during 5–10 min early after coronary reperfusion and before stenting would prevent and 
reduce MVO. 1527 patients had been screened and 440 (28.8%) had been randomized (placebo, 
n=151; alteplase 10 mg, n=144; alteplase 20 mg, n=145) when the Data and Safety Monitoring 
Committee recommended that enrolment be discontinued due to futility. The amount (mean, standard 
deviation) of MVO did not differ between the groups [2.32 (4.31) vs. 2.61 (4.49) vs. 3.48 (5.83) % 
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LV mass); p=0.43] (111). In the trial led by Morales-Ponce et al. (113), 76 patients with anterior 
STEMI were randomized to treatment with either intra-coronary tenecteplase or intravenous 
abciximab. At 4 months, infarct size measured by CMR was not different between the groups. In 
RESTORE-MI, enrolment involves a stratified approach with patient selection based on an increased 
IMR (>32) measured at the end of PCI. RESTORE-MI and STRIVE were designed as phase 3 trials 
and are still ongoing. 
 
Interventional procedures 
Despite initial promising results, routine manual thrombus aspiration performed during 
primary PCI failed to demonstrate a clinical benefit in STEMI patients. Indeed, the TASTE trial 
randomized 7,244 patients with STEMI to manual thrombus aspiration or to conventional primary 
PCI. Death from any cause after 30 days occurred in 2.8% and in 3.0% of patients, respectively (114). 
After 1 year, no mortality benefit was associated with manual thrombus aspiration (115). Moreover, 
the TOTAL trial showed that, in patients with STEMI undergoing primary PCI, routine manual 
thrombectomy when compared with PCI alone did not reduce the risk of cardiovascular death, 
recurrent MI, cardiogenic shock, or NYHA class IV heart failure within 180 days but was associated 
with an increased rate of stroke within 30 days (116). On the other hand, the JETSTENT study, 
including patients with angiographic evidence of a large thrombus burden, evaluated the Angiojet 
mechanical thrombectomy device showing an acute improvement in STR and a lower MACE rate at 
1-year in the Angiojet group compared with the direct stenting group (117). 
Moreover, pressure-controlled intermittent coronary sinus occlusion (PICSO) may improve 
microvascular perfusion after primary PCI and has been shown to reduce infarct size both in 
experimental and small clinical studies (118). However, evidence of improved clinical outcome is 
still lacking. 
Finally, hypothermia induced by cold saline and endovascular cooling failed to show a 
reduction of IS and MVO (13). 
 19 
Future therapeutic approaches and gaps in knowledge 
It is evident that most of the cardioprotection studies performed in the last decades mainly 
addressed infarct size as endpoint, but they failed to translate the evidence of a reduced infarct size 
into improved clinical outcomes. Of note, cardiomyocyte death occurs as a result of the combined 
effect on multiple players within the cardiac tissue. In particular, the coronary microcirculation 
represents an important therapeutic target and the effect of studied therapies on the occurrence of 
MVO was often not adequately assessed. Moreover, as discussed above, recent studies suggested a 
prognostic value of MVO over MI size. Thus, further studies specifically addressing the effect of 
therapies on MVO over infarct size are needed and this remains an unmet medical need. 
Although the discussed treatment options address specific mechanisms, which contribute to 
the occurrence of MVO, no approach clearly demonstrated superiority when applied in unselected 
patient cohorts with MI. Thus, the currently available data for the prevention and treatment 
approaches regarding MVO might best be described as weak or suggestive. This is also reflected in 
the current guidelines for Europe and the US, which mention the lack of a definitive proof of therapies 
to treat or prevent MVO. Therefore, future research efforts should be directed to evaluate potential 
benefits in high-risk subgroups, which are prone to develop MVO, e.g. patients with high thrombus 
burden or spastic coronary arteries, and in different time windows in the course of MI before, during 
and after primary PCI. The dynamic pattern of MVO (119) with an increase over the first 48 hours 
after infarction followed by a stable period for several days and complete resolution within weeks to 
months might also provide mechanistic insights into the causes of microvascular dysfunction. A 
potential association between the timing of peak MVO or the length of its persistence with underlying 
mechanisms could enable targeted treatment approaches and should be evaluated in future studies. 
In particular, modulation of inflammatory responses may represent a potential therapeutic 
target not fully explored. Indeed, acute ischemia-reperfusion injury during STEMI triggers an initial 
inflammatory reaction with the purpose to remove necrotic debris from the MI zone. However, a 
robust inflammatory response may lead to the occurrence of a significant interstitial myocardial 
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edema that not only is a consequence of sustained myocardial ischemia/reperfusion injury but also 
contributes to MVO by compressing capillaries and small arterioles and further decreasing flow 
through this dysfunctional microcirculation (13). Moreover, the persistence of an inflammatory 
process in the chronic phase after MI may contribute to the occurrence of adverse ventricular 
remodelling and worse clinical outcomes (120). Of note, statins represent one of the treatments able 
to attenuate inflammation in the context of MI, and probably the positive results of previous reported 
studies may be in part due to their anti-inflammatory effect (75-78). However, specific therapies 
addressing inflammation have been disappointing overall and newer treatments are needed (120). 
Probably, a tailored anti-inflammatory approach in patients with evidence of significant myocardial 
edema at CMR may select patients that effectively benefit from this treatment. 
Of interest, emerging data suggest that severe MVO and IMH at the time of primary PCI leads 
to residual myocardial iron during the chronic phase after MI, and it may be a source of prolonged 
inflammation and have an impact on adverse LV remodelling (121). Of note, a small randomized, 
double-blind, placebo-controlled study (122) using iron chelation with deferoxamine (500 mg 
immediately before primary PCI followed by a 12-h infusion) to target ischemia-reperfusion injury 
in patients with STEMI treated by primary PCI, failed to show a significant difference in the primary 
endpoint of MI size determined by CMR. However, deferoxamine effectively decreased serum iron 
levels and oxidative stress as measured by plasma F2-isoprostanes after primary PCI. Of note, a 
limitation of this study was administration of iron chelation therapy in all unselected STEMI patients. 
Further studies administering deferoxamine only in patients with evidence of IMH at CMR might 
produce different results. 
Furthermore, pericytes are contractile cells on the walls of capillaries and are reported to be 
the second most-common cell type in the heart, and they may represent a potential therapeutic target 
(123). Indeed, pericytes can irreversibly constrict coronary capillaries after myocardial ischemia, 
reducing reperfusion and contributing to the occurrence of MVO, and intracoronary administration 
of adenosine, endothelin antagonists and verapamil may be able to relax pericytes (123). 
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Finally, as multiple cellular players and different signalling pathways are involved in 
determining both infarct size and the occurrence of MVO, a multi-targeted approach using a 
combination of therapies may be a more effective way to obtain an effective cardioprotection that 
translate into improved clinical outcome. Accordingly, recent studies evaluating a multi-targeted 
approach showed promising results (99,105, 106, 124). 
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Table 1 Potential benefits of pharmacological strategies in reducing infarct size and clinical outcomes in STEMI patients 
Drugs Studies Setting Endpoints  Results Potential effect on 
cardiomyocytes 
Potential effect on 
microcirculation 
Ref 
Beta-blockers METOCARD-CNIC 
iv metoprolol up to 
15mg before 
reperfusion 
STEMI 
 
 
 
Infarct size (CMR 
at 5-7days) 
 
↓ infarct size  
 
↓ O2 consumption  Inhibition of neutrophil–platelet 
co-aggregation 
 
 
 
 
41,42 
EARLY BAMI 
iv metoprolol  
two bolus of 5mg 
before reperfusion 
STEMI Infarct size 
(CMR at 30 days) 
No effect 44 
        
Adenosine AMISTAD-II 
3-h infusion of 
adenosine 50 or 70 
microg/kg/min started 
within 15 min either of 
the start of fibrinolysis 
or before coronary 
intervention 
STEMI 
 
 
Composite of 
chronic heart 
failure (HF), 
rehospitalization 
for HF and 
death at 
6 months; infarct 
size (technetium-
99m sestamibi) 
No differences 
in clinical 
outcomes; 
↓infarct size  
 
 
↓ Afterload  
↓ ATP breakdown  
↓ Cellular Ca2+ influx 
↓ Oxidative stress 
↑ Coronary microvascular 
vasodilation 
↓ Neutrophil adherence and 
neutrophil-mediated 
cellular damage 
↓ Platelet aggregation 
↓ Oxidative stress 
45,46 
REFLO-STEMI 
Intracoronary 
adenosine 1–2 mg 
during PCI 
STEMI Infarct size and 
MVO  
(CMR at 2–4 
days) 
No effect 49 
        
GLP-1 analogue 
Exenatide 
Lønborg J et al. 
i.v. infusion of 
exenatide started 15 
min prior to PPCI and 
continued for 6 h 
STEMI Salvage index 
(myocardial area 
at risk measured 
in the acute 
phase/final infarct 
size at CMR) 
↓ Salvage index 
and infarct size 
↑ Pro-survival signaling 
pathways 
↓ Apoptosis 
↑ Glucose uptake 
↓ Macrophage migration 
↑ Microvascular recruitment 
52 
 Woo et al s.c. 
injection of Exenatide 
prior to PCI 
STEMI Infarct size 
(CKMB, Tn and 
CMR) 
↓ Infarct size 53 
        
 43 
Statins SECURE PCI 
Atorvastatin 80mg 
before and 24 hours 
after a planned PCI 
STEMI Composite of all-
cause mortality, 
myocardial 
infarction, stroke, 
and unplanned 
coronary 
revascularization 
at 30 days. 
No effect Unknown ↑ Microvascular dilation 
↑ Endothelial function 
↓ Platelet activation 
↓ Inflammation 
↓ Immune response 
 
57 
 Hahn et al 
Atorvastat 80mg 
before PCI and for 5 
days after PCI 
STEMI Infarct size 
(assessed by 
technetium Tc 
99m tetrofosmin) 
No effect 13 
        
Atrial 
natriuretic 
peptide 
J-WIND 
iv carperitide 72 h 
infusion started prior 
to PPCI 
STEMI Infarct size 
(CKMB) and 
LVEF 
↓ Infarct size 
↑ LEVF 
↓ End-diastolic pressure 
↑ Coronary collateral blood 
flow 
↑ Mitochondrial potassium 
ATP channel activation 
↓ Neutrophils-induced 
endothelial cytotoxity 
60 
        
Intracoronary 
fibrinolytic 
therapy 
 
T-TIME 
intracoronary alteplase 
10 mg or 20 mg during 
PPCI (after reperfusion 
of the infarct-related 
coronary artery and 
before stent implant) 
 
 
STEMI MVO by CMR at 
day 2 to 7 
No effect Unknown ↓ Intracoronary clot 89 
P2Y12 inhibitor PITRI  
(ongoing) 
Cangrelor 
iv bolus followed by an 
infusion prior to PCI 
STEMI Myocardial 
infarct size by 
CMR at Day 2 to 
7 
 ↑ Pro-survival signaling 
pathway 
 
Platelet inhibition 
 
65 
 CvLPRIT-CMR 
Clopidogrel versus 
Prasugrel or 
Ticagrelor before 
hospital arrival or in 
hospital at arrival 
STEMI Myocardial 
infarct size at 
CMR 
↓ Infarct size 
(Ticagrelor and 
Prasugrel>Clopi
dogrel) 
 Platelet inhibition‡ 
 
13 
 44 
‡Ticagrelor also exerts adenosine-mediated effects. 
        
GP IIb/IIIa 
receptor 
inhibitors 
 
INFUSE AMI 
Intracoronary 
abciximab at the time 
of PCI 
STEMI Infarct size at 30 
days assessed by 
CMR 
↓ Infarct size Unknown Platelet inhibition 
 
71 
        
Cyclosporin A CYCLE 
iv Ciclosporin-A- 
Sandimmune at the 
time of PCI 
STEMI 
 
 
incidence of 
≥70% ST-
segment 
resolution 60 min 
after TIMI flow 
grade 3; 
(secondary 
endpoints 
included high-
sensitivity cardiac 
troponin T) 
No effect 
 
 
↓ Apoptosis by reducing 
mitochondrial permeability 
↑ Endothelial function 76 
 CIRCUS 
iv Cyclosporin A- 
Ciclomulsion at the 
time of PCI 
 
STEMI Composite of 
death from any 
cause, worsening 
of HF, HF 
rehospitalization, 
or adverse LV 
remodeling at 1 
year (by echo). 
No effect 3 
        
N-acetylcysteine NACIAM Trial 
iv N-acetylcysteine with 
background low-dose 
nitroglycerin at the 
time of PCI 
STEMI Infarct size at 
CMR 
↓ infarct size ↓ Oxidative stress (ROS 
scavenger) 
↓ Oxidative stress (ROS 
scavenger) 
77 
 LIPSIA-NACC Trial 
iv N-acetylcysteine 
STEMI Myocardial 
salvage index at 
CMR 
No effect   78 
Table 2 Recommendations for future cardioprotection studies. 
 
Strategy Comment 
MVO as a primary therapeutic target Previous studies mainly focused on myocardial injury 
and infarct size as primary target for cardioprotection 
studies. However, future studies should evaluate 
systematically the effects of cardioprotective therapies 
on MVO, along with infarct size  
Multi-targeted approach  Previous studies reported neutral results probably 
because they were based on a pharmacological strategy 
directed to a single target, an approach that may be 
ineffective given that ischemia/reperfusion injury is a 
complex process with different signalling cascades and 
multiple cellular players (cardiomyocytes, endothelial 
cells, fibroblasts, inflammatory cells, platelets). A multi-
targeted approach with a combination of therapies may 
be a more effective approach to cardioprotection in the 
clinical setting. 
Proper selection of enrolled patients A proper selection of patients included in 
cardioprotective studies is crucial.  In particular, 
patients less likely to benefit from cardioprotective 
therapies (i.e. patients spontaneously reperfused prior 
to PPCI, with small AAR or with ischaemic times >12 h) 
should be excluded, focusing on patients presenting 
with a large AAR >30% of the LV, usually involving 
proximal or mid left anterior descending coronary 
artery and with shorter ischaemic times (<4 h). 
Personalized therapeutic approach 
based on the mechanism responsible 
for MVO 
Assessment of dynamic changes in time course of MVO 
after STEMI may elucidate if different mechanisms act 
in different manner in each patient, thus ensuring a 
personalized therapeutic approach (i.e. aggressive 
antithrombotic therapy in patients with MVO mainly 
due to distal embolization or anti-inflammatory 
therapy in patients with MVO deriving from 
extravascular compression from interstitial oedema). 
Standardization of imaging protocols 
and clinical endpoints 
The imaging protocols in previous studies were quite 
heterogeneous, hampering inter-study comparisons 
and collaborative research with data merging. Thus, a 
standardization of post-infarction CMR imaging 
protocols is urgently needed to further strengthen CMR 
as the reference method to in cardioprotection studies. 
Moreover, only clinical endpoints that are relevant to 
 46 
cardioprotection should be considered (i.e. acute and 
chronic MI size, LV size and ejection fraction). 
 
Legend: AAR: area-at-risk; CMR: cardiac magnetic resonance; LV: left ventricle; MVO: microvascular 
obstruction; PPCI: primary percutaneous coronary intervention. 
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Figure legends 
 
Figure 1. Pathogenic mechanisms involved in coronary microvascular obstruction and 
cardiomyocyte death. 
 
Figure 2. Relationship and prognostic significance of infarct size and MVO. Reprinted with 
permission from Eitel et al. J Am Coll Cardiol 2014;64:1217-1226. Hazard ratios refer to the 
multivariate analysis of Eitel et al. J Am Coll Cardiol 2014;64:1217-1226. 
 
Figure 3. Visualisation of MVO and IMH by CMR. Visualization of microvascular obstruction (A) 
and intramyocardial haemorrhage (B) (arrows) on short-axis late gadolinium-enhanced (A) and T2* 
mapping (B). Cardiac magnetic resonance images were performed 4 days after acute ST-elevation 
myocardial infarction due to occlusion of the left anterior descending artery. 
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Figure 1 
 
 
Figure 2 
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Figure 3 
 
 
